Buprenorphine Treatment Centers in New Hampshire

For methadone and buprenorphine, continued opioid use during induction is common and expected; the medication itself helps stop use. For naltrexone, however, you must complete a 7–14 day opioid-free period first. Your New Hampshire clinician will tailor the induction based on your medication.

It depends on the program. Bundled MAT programs include counseling in a single weekly or monthly fee. Others bill counseling separately ($40–$150 per session). New Hampshire Medicaid (Granite Advantage) and most commercial plans cover both components when delivered by a licensed provider.

Yes. New Hampshire Medicaid (Granite Advantage) covers FDA-approved medications for opioid use disorder, including buprenorphine, plus the associated counseling, drug testing, and clinic visits. Specific formulary details (preferred agents, long-acting injectables) vary by plan — check with your New Hampshire Medicaid (Granite Advantage) managed-care organization.

You may owe the full charge minus any out-of-network benefit. Ask buprenorphine providers whether they will file an insurance claim, charge you up-front, or negotiate a single-case agreement with your insurer. No Surprises Act protections may apply — request a Good Faith Estimate.

Yes — federal Congress eliminated the X-waiver in December 2022, so any New Hampshire clinician with a DEA registration can now prescribe buprenorphine for OUD. Continuing-education requirements apply; training is free through Providers Clinical Support System (PCSS) and SAMHSA.

Yes. Cross-titration between methadone and buprenorphine is a routine clinical maneuver in New Hampshire. Transfer from methadone to buprenorphine is technically more challenging (risk of precipitated withdrawal) and usually requires a structured micro-induction protocol supervised by an experienced clinician.

Bring a photo ID, insurance or New Hampshire Medicaid (Granite Advantage) card (if applicable), and a list of current medications. Proof of address and pharmacy information speed up buprenorphine prescribing. Intake staff will walk you through paperwork at your first visit.

First doses are intentionally cautious — 5–10 mg of buprenorphine or 20–30 mg of methadone — to assess tolerance and avoid over-sedation. Your dose is titrated up over the first 1–2 weeks until cravings and withdrawal are controlled.

Methadone can prolong the QTc interval on ECG; New Hampshire clinics screen patients with baseline and follow-up ECGs. Buprenorphine and naltrexone do not carry this risk. Patients with cardiac disease can safely use MAT under close cardiology and MAT-team coordination.

Yes. Starting MAT during pregnancy is strongly recommended for patients with OUD. New Hampshire perinatal-addiction programs offer priority same-day access; OB-MAT coordinated care improves maternal and infant outcomes dramatically compared to untreated OUD.

Patients prescribed buprenorphine or naltrexone in New Hampshire can technically receive medication without counseling, but outcomes are significantly better with integrated counseling. Methadone patients at OTPs have counseling requirements per federal rule 42 CFR Part 8.

Only if disclosed under very narrow conditions — typically with your consent or specific court order. Being on prescribed buprenorphine is legally protected and should not be used against you as a parent. Keep documentation of stability; consult a family-law attorney.